Cilengitide: A Prototypic Integrin Inhibitor for the Treatment of Glioblastoma and Other Malignancies

Genes and Cancer

Volumn 2, Issue 12, 2011, Pages 1159-1165

  Reardon, David A ^a   Cheresh, David ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiogenesis; glioblastoma; integrins; invasion; malignant glioma

Indexed keywords

CETUXIMAB; CILENGITIDE; CISPLATIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; TEMOZOLOMIDE;

BRAIN HEMORRHAGE; CHEMORADIOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84868621665     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912450586     Document Type: Review

References (61)

1. Courter DL,Lomas L,Scatena M, et al.Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor- kappaB.J Biol Chem. 2005;280:12145-51.
2. Scatena M,Almeida M,Chaisson ML, et al.NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival.J Cell Biol. 1998;141:1083-93.
3. Aoudjit F,Vuori K.Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells.Oncogene. 2001;20:4995-5004.
4. Ricono JM,Huang M,Barnes LA, et al.Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis.Cancer Res. 2009;69:1383-91.
5. Dolfi F,Garcia-Guzman M,Ojaniemi M, et al.The adaptor protein Crk connects multiple cellular stimuli to the JNK signaling pathway.Proc Natl Acad Sci U S A. 1998;95:15394-9.
6. Miyamoto S,Teramoto H,Gutkind JS, et al.Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors.J Cell Biol. 1996;135:1633-42.
7. Desgrosellier JS,Cheresh DA.Integrins in cancer: biological implications and therapeutic opportunities.Nat Rev Cancer. 2010;10:9-22.
8. Skuli N,Monferran S,Delmas C, et al.Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.Cancer Res. 2009;69:3308-16.
9. Bello L,Francolini M,Marthyn P, et al.Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.Neurosurgery. 2001;49:380-9.
10. Gladson CL,Cheresh DA.Glioblastoma expression of vitronectin and the alpha v beta 3 integrin: adhesion mechanism for transformed glial cells.J Clin Invest. 1991;88:1924-32.
11. Bello L,Carrabba G,Giussani C, et al.Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.Cancer Res. 2001;61:7501-6.
12. Taga T,Suzuki A,Gonzalez-Gomez I, et al.Alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.Int J Cancer. 2002;98:690-7.
13. Gladson CL.The extracellular matrix of gliomas: modulation of cell function.J Neuropathol Exp Neurol. 1999;58:1029-40.
14. Gladson CL,Wilcox JN,Sanders L, et al.Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors.J Cell Sci. 1995;108 (Pt 3): 947-56.
15. Vitolo D,Paradiso P,Uccini S, et alExpression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology; 1996:521-8.
16. Baker EL,Zaman MH.The biomechanical integrin.J Biomech. 2010;43:38-44.
17. Alghisi GC,Ruegg C.Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.Endothelium. 2006;13:113-35.
18. Dechantsreiter MA,Planker E,Matha B, et al.N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.J Med Chem. 1999;42:3033-40.
19. Friedlander M,Brooks PC,Shaffer RW, et al.Definition of two angiogenic pathways by distinct alpha v integrins.Science. 1995;270:1500-2.
20. Hammes HP,Brownlee M,Jonczyk A, et al.Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization.Nat Med. 1996;2:529-33.
21. Albert DH,Tapang P,Magoc TJ, et al.Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.Mol Cancer Ther. 2006;5:995-1006.
22. Loges S,Butzal M,Otten J, et al.Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.Biochem Biophys Res Commun. 2007;357:1016-20.
23. Nisato RE,Tille JC,Jonczyk A, et al.Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.Angiogenesis. 2003;6:105-19.
24. Reynolds AR,Hart IR,Watson AR, et al.Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.Nat Med. 2009;15:392-400.
25. Avraamides CJ,Garmy-Susini B,Varner JA.Integrins in angiogenesis and lymphangiogenesis.Nat Rev Cancer. 2008;8:604-17.
26. Garmy-Susini B,Jin H,Zhu Y, et al.Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation.J Clin Invest. 2005;115:1542-51.
27. Jin H,Aiyer A,Su J, et al.A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature.J Clin Invest. 2006;116:652-62.
28. Asselin-Labat ML,Sutherland KD,Barker H, et al.Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.Nat Cell Biol. 2007;9:201-9.
29. Luo M,Fan H,Nagy T, et al.Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.Cancer Res. 2009;69:466-74.
30. Samanna V,Wei H,Ego-Osuala D, et al.Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells.Exp Cell Res. 2006;312:2214-30.
31. Vaillant F,Asselin-Labat ML,Shackleton M, et al.The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis.Cancer Res. 2008;68:7711-7.
32. Lathia C,Lettieri J,Cihon F, et al.Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.Cancer Chemother Pharmacol. 2006;57:685-92.
33. Lorger M,Krueger JS,O'Neal M, et al.Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.Proc Natl Acad Sci U S A. 2009;106:10666-71.
34. Goodman SL,Holzemann G,Sulyok GA, et al.Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.J Med Chem. 2002;45:1045-51.
35. Cheresh DA.Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor.Proc Natl Acad Sci U S A. 1987;84:6471-5.
36. Mitjans F,Meyer T,Fittschen C, et al.In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.Int J Cancer. 2000;87:716-23.
37. MacDonald TJ,Taga T,Shimada H, et al.Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.Neurosurgery. 2001;48:151-7.
38. Mikkelsen T,Brodie C,Finniss S, et al.Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.Int J Cancer. 2009;124:2719-27.
39. Tentori L,Dorio AS,Muzi A, et al.The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.Oncol Rep. 2008;19:1039-43.
40. Burke PA,DeNardo SJ,Miers LA, et al.Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.Cancer Res. 2002;62:4263-72.
41. Albert JM,Cao C,Geng L, et al.Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.Int J Radiat Oncol Biol Phys. 2006;65:1536-43.
42. Maurer GD,Tritschler I,Adams B, et al.Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.Neuro Oncol. 2009;11:747-56.
43. Hegi ME,Liu L,Herman JG, et al.Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.J Clin Oncol. 2008;26:4189-99.
44. Eskens FA,Dumez H,Hoekstra R, et al.Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.Eur J Cancer. 2003;39:917-26.
45. Hariharan S,Gustafson D,Holden S, et al.Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.Ann Oncol. 2007;18:1400-7.
46. Nabors LB,Mikkelsen T,Rosenfeld SS, et al.Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.J Clin Oncol. 2007;25:1651-7.
47. MacDonald TJ,Stewart CF,Kocak M, et alPhase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol; 2008:919-24.
48. Reardon DA,Fink KL,Mikkelsen T, et al.Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.J Clin Oncol. 2008;26:5610-7.
49. de Groot JF,Lamborn KR,Chang SM, et alPhase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol; 2011:2689-95.
50. Stupp R,Hegi ME,Neyns B, et al.Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.J Clin Oncol. 2010;28:2712-8.
51. Hegi ME,Diserens AC,Gorlia T, et al.MGMT gene silencing and benefit from temozolomide in glioblastoma.N Engl J Med. 2005;352:997-1003.
52. Stupp R,Dietrich PY,Ostermann Kraljevic S, et al.Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.J Clin Oncol. 2002;20:1375-82.
53. Stupp R,Mason WP,van den Bent MJ, et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med. 2005;352:987-96.
54. Nabors LB,Mikkelsen T,Batchelor T, et al.NABTT 0306: a randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM).J Clin Oncol. 2009;27:.
55. Curran WJ,Scott CB,Horton J, et al.Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.J Natl Cancer Inst. 1993;85:704-10.
56. Schnell O,Krebs B,Carlsen J, et al.Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography.Neuro Oncol. 2009;11:861-70.
57. Dumont RA,Hildebrandt I,Su H, et al.Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.Cancer Res. 2009;69:3173-9.
58. Khemtong C,Kessinger CW,Ren J, et al.In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles.Cancer Res. 2009;69:1651-8.
59. Ebos JM,Lee CR,Cruz-Munoz W, et al.Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.Cancer Cell. 2009;15:232-9.
60. Paez-Ribes M,Allen E,Hudock J, et al.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.Cancer Cell. 2009;15:220-31.
61. Gilbert MR, et al.J Neurooncology Jan. 2012;106 (1): 147-53.